Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.

Moreland, L W

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. [electronic resource] - Arthritis and rheumatism Nov 1995 - 1581-8 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

0004-3591

10.1002/art.1780381109 doi


Adult
Aged
Antibodies, Monoclonal--adverse effects
Arthritis, Rheumatoid--therapy
CD4 Antigens--immunology
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Lymphocyte Subsets--immunology
Male
Methotrexate--therapeutic use
Middle Aged
Recombinant Fusion Proteins--adverse effects